Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea
K Takasuna, T Hagiwara, K Watanabe, S Onose… - Cancer chemotherapy …, 2006 - Springer
Purpose: An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of
solid tumor malignancy, but its severe diarrhea has often limited its more widespread use …
solid tumor malignancy, but its severe diarrhea has often limited its more widespread use …
Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats
A Kurita, S Kado, N Kaneda, M Onoue… - Cancer chemotherapy …, 2000 - Springer
Purpose: Clinically, diarrhea is the major dose-limiting toxicity of irinotecan hydrochloride
(CPT-11). Using a rat model, we attempted to decrease the incidence of delayed-onset …
(CPT-11). Using a rat model, we attempted to decrease the incidence of delayed-onset …
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
DFS Kehrer, A Sparreboom, J Verweij, P De Bruijn… - Clinical Cancer …, 2001 - AACR
This study was designed to evaluate irinotecan (CPT-11) disposition and
pharmacodynamics in the presence and absence of the broad-spectrum antibiotic …
pharmacodynamics in the presence and absence of the broad-spectrum antibiotic …
Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo
KW Cheng, CH Tseng, CC Tzeng, YL Leu… - Pharmacological …, 2019 - Elsevier
Abstract Irinotecan (CPT-11), a first-line chemotherapy for advanced colorectal cancer,
causes serious diarrhea in patients receiving treatment. The underlying mechanism has …
causes serious diarrhea in patients receiving treatment. The underlying mechanism has …
New approaches to prevent intestinal toxicity of irinotecan-based regimens
A Alimonti, A Gelibter, I Pavese, F Satta… - Cancer treatment …, 2004 - Elsevier
Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the
replication and transcription system of DNA. Irinotecan is employed, with different modalities …
replication and transcription system of DNA. Irinotecan is employed, with different modalities …
Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
K Takasuna, T Hagiwara, M Hirohashi, M Kato… - Cancer research, 1996 - AACR
Abstract Irinotecan hydrochloride (CPT-11), an antitumor camptothecin derivative, causes
severe forms of diarrhea clinically. We characterized CPT-11-induced diarrhea histologically …
severe forms of diarrhea clinically. We characterized CPT-11-induced diarrhea histologically …
Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
K Takasuna, Y Kasai, Y Kitano, K Mori… - Nihon Yakurigaku …, 1995 - europepmc.org
We investigated the mechanisms of CPT-11-induced diarrhea. 1) CPT-11 (80 mg/kg, iv)
induced watery diarrhea within 1 hr after dosing in saline-loaded (10 ml/kg, po) rats. This …
induced watery diarrhea within 1 hr after dosing in saline-loaded (10 ml/kg, po) rats. This …
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen
A Kurita, S Kado, T Matsumoto, N Asakawa… - Cancer chemotherapy …, 2011 - Springer
Abstract Irinotecan hydrochloride (CPT-11) is a useful drug for cancer chemotherapy but
sometimes induces severe diarrhea clinically. CPT-11 is mainly activated to SN-38 by …
sometimes induces severe diarrhea clinically. CPT-11 is mainly activated to SN-38 by …
Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
K Takasuna, T Hagiwara, M Hirohashi, M Kato… - Cancer chemotherapy …, 1998 - Springer
Abstract Purpose: SN-38, a metabolite of irinotecan hydrochloride (CPT-11), is considered to
play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11 …
play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11 …
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
F Saliba, R Hagipantelli, JL Misset, G Bastian… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against
colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study …
colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study …